You are here

Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

Last updated on February 16, 2020

FOR MORE INFORMATION
Study Location
Tucson, Arizona, 85404 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Acute Myeloid Leukemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Treated by Mylotarg

- Provide ICF

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Treated by Mylotarg

- Provide ICF

NCT00161668
Pfizer
Completed
Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Acute Myeloid Leukemia
NCT02038777
All Genders
20+
Years
Multiple Sites
Descriptive Information
Brief Title Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care
Official Title Prospective Observational Study of Mylotarg (Gemtuzumab Ozogamicin) in Usual Care
Brief Summary This study is designed to assess the safety of Mylotarg therapy in routine practice.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Not Provided
Study Population Not Provided
Condition Acute Myeloid Leukemia
Intervention Drug: Mylotarg
Study Groups/Cohorts Not Provided
Publications * Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Enrollment
 (submitted: September 11, 2005)
500
Original Enrollment Same as current
Study Completion Date Not Provided
Primary Completion Date Not Provided
Eligibility Criteria

Inclusion Criteria:

  • Treated by Mylotarg
  • Provide ICF
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT00161668
Other Study ID Numbers 0903X-100847
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Not Provided
Study Sponsor Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators Not Provided
Investigators
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date March 2007

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now